Future research should focus on evaluating the therapeutic potential of potassium channel inhibitors, particularly in combination strategies, to enhance antitumor immune responses and ultimately improve clinical outcomes for pancreatic cancer patients. The gene discussed is KCNA3; the disease is familial pancreatic carcinoma.